逆转潮流——人工智能在肝癌发展中的应用。

IF 4.4 2区 医学 Q1 ONCOLOGY
Cancers Pub Date : 2025-09-14 DOI:10.3390/cancers17183003
Cristiana Grapă, Tudor Mocan, Lavinia Patricia Mocan, Andrei Motofelea, Raluca Stănciulescu, Rareș Crăciun, Andrei Vârciu, Zeno Spârchez, Teodora Mocan
{"title":"逆转潮流——人工智能在肝癌发展中的应用。","authors":"Cristiana Grapă, Tudor Mocan, Lavinia Patricia Mocan, Andrei Motofelea, Raluca Stănciulescu, Rareș Crăciun, Andrei Vârciu, Zeno Spârchez, Teodora Mocan","doi":"10.3390/cancers17183003","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background/Objectives:</b> Liver cancer is an exceedingly heterogeneous malignancy with high mortality rates, and despite extensive research, there have been no significant improvements in treatment outcomes. In the process of navigating the complex landscape of liver cancer, AI has arisen as the \"knight in shining armour\", sparking hope and offering invaluable insight into early detection, diagnosis, staging, treatment selection, and post-treatment surveillance. By integrating imaging, clinical, pathological, and molecular data, AI emerges as a transformative tool that offers unique opportunities to enhance patient care. <b>Methods:</b> A comprehensive literature search of PubMed and Scopus, was conducted using the terms \"artificial intelligence,\" \"machine learning,\" \"deep learning,\" \"radiomics,\" and \"liver cancer.\" Eligible studies included peer-reviewed original research applying AI to detection, diagnosis, prognosis, treatment planning, or surveillance of liver cancer. Key findings are organized along the clinical continuum. <b>Results:</b> Imaging-based AI models for tumor detection were the most advanced, with several achieving diagnostic accuracy above 90% in retrospective studies. Applications for treatment decision-making are emerging, but most remain at proof-of-concept stages. Generally, few of these innovations have progressed to large-scale clinical trials or received regulatory approval, slowing their integration into clinical practice. <b>Conclusions:</b> This narrative review highlights AI's potential to transform liver cancer management and addresses the ethical, regulatory, and logistical barriers to its clinical adoption, serving as a call to action for integrating AI into practice to improve patient outcomes.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 18","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468571/pdf/","citationCount":"0","resultStr":"{\"title\":\"Turning the Tide-Artificial Intelligence in the Evolving Landscape of Liver Cancer.\",\"authors\":\"Cristiana Grapă, Tudor Mocan, Lavinia Patricia Mocan, Andrei Motofelea, Raluca Stănciulescu, Rareș Crăciun, Andrei Vârciu, Zeno Spârchez, Teodora Mocan\",\"doi\":\"10.3390/cancers17183003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background/Objectives:</b> Liver cancer is an exceedingly heterogeneous malignancy with high mortality rates, and despite extensive research, there have been no significant improvements in treatment outcomes. In the process of navigating the complex landscape of liver cancer, AI has arisen as the \\\"knight in shining armour\\\", sparking hope and offering invaluable insight into early detection, diagnosis, staging, treatment selection, and post-treatment surveillance. By integrating imaging, clinical, pathological, and molecular data, AI emerges as a transformative tool that offers unique opportunities to enhance patient care. <b>Methods:</b> A comprehensive literature search of PubMed and Scopus, was conducted using the terms \\\"artificial intelligence,\\\" \\\"machine learning,\\\" \\\"deep learning,\\\" \\\"radiomics,\\\" and \\\"liver cancer.\\\" Eligible studies included peer-reviewed original research applying AI to detection, diagnosis, prognosis, treatment planning, or surveillance of liver cancer. Key findings are organized along the clinical continuum. <b>Results:</b> Imaging-based AI models for tumor detection were the most advanced, with several achieving diagnostic accuracy above 90% in retrospective studies. Applications for treatment decision-making are emerging, but most remain at proof-of-concept stages. Generally, few of these innovations have progressed to large-scale clinical trials or received regulatory approval, slowing their integration into clinical practice. <b>Conclusions:</b> This narrative review highlights AI's potential to transform liver cancer management and addresses the ethical, regulatory, and logistical barriers to its clinical adoption, serving as a call to action for integrating AI into practice to improve patient outcomes.</p>\",\"PeriodicalId\":9681,\"journal\":{\"name\":\"Cancers\",\"volume\":\"17 18\",\"pages\":\"\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12468571/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/cancers17183003\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17183003","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:肝癌是一种非常异质性的恶性肿瘤,死亡率高,尽管进行了广泛的研究,但治疗结果没有显著改善。在驾驭复杂的肝癌前景的过程中,人工智能已经成为“穿着闪亮盔甲的骑士”,点燃了希望,并为早期发现、诊断、分期、治疗选择和治疗后监测提供了宝贵的见解。通过整合成像、临床、病理和分子数据,人工智能成为一种变革性工具,为加强患者护理提供了独特的机会。方法:使用“人工智能”、“机器学习”、“深度学习”、“放射组学”和“肝癌”等术语对PubMed和Scopus进行全面的文献检索。符合条件的研究包括将人工智能应用于肝癌的检测、诊断、预后、治疗计划或监测的同行评审的原创研究。主要发现是根据临床连续体组织的。结果:用于肿瘤检测的基于成像的AI模型是最先进的,在回顾性研究中有几个模型的诊断准确率达到90%以上。治疗决策的应用正在出现,但大多数仍处于概念验证阶段。一般来说,这些创新很少能进入大规模临床试验或获得监管部门的批准,从而减缓了它们融入临床实践的速度。结论:这篇叙述性综述强调了人工智能在改变肝癌管理方面的潜力,并解决了临床采用人工智能的伦理、监管和后勤障碍,呼吁采取行动,将人工智能纳入实践,以改善患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Turning the Tide-Artificial Intelligence in the Evolving Landscape of Liver Cancer.

Background/Objectives: Liver cancer is an exceedingly heterogeneous malignancy with high mortality rates, and despite extensive research, there have been no significant improvements in treatment outcomes. In the process of navigating the complex landscape of liver cancer, AI has arisen as the "knight in shining armour", sparking hope and offering invaluable insight into early detection, diagnosis, staging, treatment selection, and post-treatment surveillance. By integrating imaging, clinical, pathological, and molecular data, AI emerges as a transformative tool that offers unique opportunities to enhance patient care. Methods: A comprehensive literature search of PubMed and Scopus, was conducted using the terms "artificial intelligence," "machine learning," "deep learning," "radiomics," and "liver cancer." Eligible studies included peer-reviewed original research applying AI to detection, diagnosis, prognosis, treatment planning, or surveillance of liver cancer. Key findings are organized along the clinical continuum. Results: Imaging-based AI models for tumor detection were the most advanced, with several achieving diagnostic accuracy above 90% in retrospective studies. Applications for treatment decision-making are emerging, but most remain at proof-of-concept stages. Generally, few of these innovations have progressed to large-scale clinical trials or received regulatory approval, slowing their integration into clinical practice. Conclusions: This narrative review highlights AI's potential to transform liver cancer management and addresses the ethical, regulatory, and logistical barriers to its clinical adoption, serving as a call to action for integrating AI into practice to improve patient outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信